HDAC-IN-64
HDAC-IN-64 (Compound 13) is a HDAC inhibitor. HDAC-IN-64 inhibits HDAC4/5/6/7/9 with IC50s of 24, 45, 85, 31, 37 nM. HDAC-IN-64 has anti-proliferative activity and anti-migration properties on prostate cancer (PCA) cells. HDAC-IN-64 inhibits LNCaP and RWPE-1 cell growth with GI50 of 0.32 and 1.1 μM respectively[1].
Product Specifications
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hdac-in-64.html
Solubility
10 mM in DMSO
Smiles
NC1=NC(Cl)=C2N=CN(CC3=CC=C(C4=NOC(C(F)(F)F)=N4)C=C3F)C2=N1
Molecular Formula
C15H8ClF4N7O
Molecular Weight
413.72
References & Citations
[1]Moi D, et al. Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer. Eur J Med Chem. 2023 Aug 16;260:115730.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
P9198-02M-APC 100 µL
PUMA, BH3 domain (p53 Upregulated Modulator of Apoptosis, BCL2 Binding Component 3, BCL-2 Binding Component 3, BBC3, JFY1, JFY-1, p53 Up-regulated Modulator of Apoptosis, PUMA alpha, PUMA/JFY1) (APC)
Sign In for Pricing
View Details 
IRTAMSCD1172B8CAFLE1MG 1 mg
Anti Mouse CD117 Flow Cytometry Monoclonal Clone 2B8 Azide Free Low Endotoxin 1MG
Sign In for Pricing
View Details